Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

 Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

Shots:
  • Celgene to get non-exclusive rights for Aprinoia’s bAPN-1607 and Aprinoia to receive license and usage fee annually
  • The focus of the agreement is utilize Aprinoia’s APN-1607 in developing therapies by understanding tau pathology in rare tauopathies including Alzheimer’s Disease
  • APN-1607 is [18F]-labeled PET imaging tracer, enabling to visualize tau pathology in diverse tauopathies, MCI, dementia due AD, CBS, and PSP and is evaluated in the US, Japan, Taiwan, and China

Click here to read full press release/ article | Ref: Prnewswire | Image: Wsj

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post